2016
Multiple sclerosis
Axisa PP, Hafler DA. Multiple sclerosis. Current Opinion In Neurology 2016, 29: 345-353. PMID: 27058221, PMCID: PMC7882195, DOI: 10.1097/wco.0000000000000319.Peer-Reviewed Original ResearchConceptsMultiple sclerosisGenome-wide association studiesAssociation studiesMultiple sclerosis (MS) etiologyMultiple sclerosis progressionMultiple sclerosis patientsHigh-throughput genetic analysisImmune cell functionNumerous candidate biomarkersWide association studyMechanisms of neurodegenerationImmunomodulatory treatmentSclerosis patientsClinical outcomesTreatment arsenalDisease progressionImmune regulationSclerosisNew biomarkersCandidate biomarkersPatient careGenetic variationGenetic analysisCell functionProgression
2007
New Therapeutic Approaches for Multiple Sclerosis
De Jager PL, Hafler DA. New Therapeutic Approaches for Multiple Sclerosis. Annual Review Of Medicine 2007, 58: 417-432. PMID: 17217332, DOI: 10.1146/annurev.med.58.071105.111552.Peer-Reviewed Original ResearchConceptsCentral nervous systemMultiple sclerosisNeurodegenerative componentImmunology of MSLarge unmet clinical needSubset of patientsUnderlying pathophysiologic processEffective immunomodulatory treatmentsEntry of lymphocytesNew therapeutic approachesUnmet clinical needCategories of diseaseImmunomodulatory treatmentInflammatory componentCurrent therapiesImmune homeostasisImmune responseIndividual patientsPathophysiologic processesTherapeutic approachesTreatment approachesNervous systemPatientsHealthy profileClinical need
1999
Treatment of progressive multiple sclerosis with pulse cyclophosphamidel methylprednisolone: Response to therapy is linked to the duration of progressive disease
Hohol M, Olek M, Orav E, Stazzone L, Hafler D, Khoury S, Dawson D, Weiner H. Treatment of progressive multiple sclerosis with pulse cyclophosphamidel methylprednisolone: Response to therapy is linked to the duration of progressive disease. Multiple Sclerosis Journal 1999, 5: 403-409. PMID: 10618696, DOI: 10.1177/135245859900500i606.Peer-Reviewed Original ResearchConceptsProgressive multiple sclerosisDuration of progressionMultiple sclerosisProgressive diseaseSecondary progressive multiple sclerosisDuration of MSPrimary progressive patientsProgressive MS patientsPositive clinical responseOpen-label fashionClinical outcome measuresStart of treatmentOnset of diseaseMethylprednisolone therapySecondary progressiveImmunomodulatory treatmentImmunosuppressive therapyProgressive patientsClinical responsePatient characteristicsMS patientsImmunosuppressive agentsAutoimmune diseasesLabel fashionEDSS change